195 related articles for article (PubMed ID: 29462248)
21. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract][Full Text] [Related]
22. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
23. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
24. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C;
Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431
[TBL] [Abstract][Full Text] [Related]
26. The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Woopen H; Richter R; Inci G; Alavi S; Chekerov R; Sehouli J
Support Care Cancer; 2020 Apr; 28(4):1997-2003. PubMed ID: 31385100
[TBL] [Abstract][Full Text] [Related]
27. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
[TBL] [Abstract][Full Text] [Related]
29. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
[TBL] [Abstract][Full Text] [Related]
30. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
31. Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting.
Francis KE; Gebski V; Lord SJ; Friedlander M; Pujade-Lauraine E; Lee CK
Eur J Cancer; 2021 May; 148():251-259. PubMed ID: 33756421
[TBL] [Abstract][Full Text] [Related]
32. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
34. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
35. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
40. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Dockery LE; Rubenstein AR; Ding K; Mashburn SG; Burkett WC; Davis AM; Doo DW; Arend RC; Moore KN; Gunderson CC
Gynecol Oncol; 2019 Nov; 155(2):201-206. PubMed ID: 31522837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
